Zika virus as a cause of fever and rash

CCDR

Volume 42-3, March 3, 2016: Infectious Disease as Chronic Disease

Case Report

Zika virus, an emerging flavivirus, as a cause of fever and rash in a traveller returning from Central America

Teale A1, Payne M2,3, England J1, Morshed M4, Hull M1,5*

Affiliations

1 Department of Medicine, University of British Columbia, Vancouver, BC

2 Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC

3 Providence Health Care, Vancouver, BC

4 British Columbia Centre for Disease Control (BCCDC), Vancouver, BC

5 British Columbia Centre for Excellence in HIV/AIDS, BC

Correspondence

mhull@cfenet.ubc.ca

Suggested citation

Teale A, Payne M, England J, Morshed M, Hull M. Zika virus, an emerging flavivirus, as a cause of fever and rash in a traveller returning from Central America. Can Comm Dis Rep 2016;42:68-71. https://doi.org/10.14745/ccdr.v42i03a04

Abstract

Fever in a returning traveller is a common clinical scenario for physicians in primary and acute care. Differential diagnoses for these patients are generated based on presenting clinical symptoms, travel destinations, potential exposure activities as well as the incubation period of common etiologic agents. In a case of fever and rash in a woman returning to Canada from El Salvador in November 2015, measles, dengue and chikungunya viral infections were queried as possible causes. Subsequent molecular testing using amplification of conserved regions of the flavivirus genome from nasopharyngeal and urine samples was positive, suggesting an active flavivirus infection. Sequencing was significant for the identification of Zika virus, a flavivirus that has only recently become endemic to Brazil and is now emerging throughout Central America. Zika virus should now be included in the differential diagnosis for travellers returning from Central and South America with a febrile illness and rash. This is the first reported case of Zika virus in Canada related to the most recent outbreak in Central America, South America and the Caribbean.

Introduction

Zika virus is an emerging arthropod-borne member of the flavivirus genus that is closely related to other medically significant viruses including dengue, Japanese encephalitis virus, West Nile virus and yellow fever virus Footnote 1. Initially isolated from the Zika Forest in Uganda in 1947 Footnote 2 epidemiological surveys have shown evidence of serologic exposure in African countries including Gabon, Nigeria, Central African Republic and Sierra Leone Footnote 3Footnote 4Footnote 5Footnote 6 as well as in Southeast Asia, notably Indonesia, Malaysia and Thailand Footnote 7Footnote 8Footnote 9Footnote 10. Mosquitoes from the Aedes genus have been implicated as the primary vector of transmission of Zika virus Footnote 11. Recent outbreaks have occurred in several island nations in the South Pacific Ocean including Micronesia in 2007 Footnote 12 as well as French Polynesia, New Caledonia and the Cook Islands in 2013 and 2014 Footnote 13. Cases of Zika virus infection were first identified in the Americas in Brazil in 2014, and autochthonous transmission has been seen in north‑eastern regions of that country Footnote 14Footnote 15. As of December 2015, cases have been reported in other countries of Latin America including Venezuela, Suriname, Paraguay, Panama, Guatemala, Mexico, Colombia and El Salvador Footnote 16.

Case

A 52-year-old woman whose past medical history was significant for Parkinson's disease presented to the emergency department with fever and a new rash after recent travel to El Salvador.

The patient immigrated to Canada in 1992 from El Salvador. The primary purpose of her recent 14-day trip was to visit friends and relatives. She did not seek pre-travel medical advice, and her vaccination status was unclear. She stayed exclusively in San Salvador, the capital city of El Salvador. She denied any animal or fresh water exposures or any new sexual contacts. She received multiple mosquito bites during her visit. She felt well throughout her trip but noted subjective fevers along with myalgias and fatigue beginning five days after her return to Canada. She also had symptoms of conjunctivitis, but this was diminishing by presentation to the emergency room. An erythematous rash had initially developed on her face and spread to her trunk and arms the following day, which prompted the patient's presentation on day five of her illness.

On arrival, the patient was afebrile and non-toxic in appearance. Review of systems was significant for mild headache with no retro-orbital discomfort. She endorsed generalized myalgias and fatigue but no specific arthralgias. The patient denied significant respiratory or gastrointestinal symptoms. Examination was significant for a blanchable, maculopapular rash over the face that extended to the trunk, arms and upper legs. There was minimal conjunctival injection and no Koplik spots were identified. Cardiovascular and respiratory examinations were unremarkable and examination of the abdomen did not demonstrate splenomegaly.

Basic investigations collected on day five of the patient's illness were sent, including a complete blood count, which revealed mild leukopenia (3.2 x 109 cells/L; reference: 3.5–10.5 x 109 cells/L) and mild thrombocytopenia (112 x 109 cells/L; reference 150–450 x 109 cells/L). Electrolytes, liver profile and renal function tests were normal. A chest x-ray was normal. Thin and thick malaria smears along with a P. falciparum rapid antigen test were negative. Rubella serology showed evidence of past infection/immunity. A monospot test was negative. HIV serology and syphilis enzyme immunoassay (EIA) were negative. Parvovirus IgM and IgG were negative. Blood cultures were negative, as was a throat culture. A throat swab for enterovirus PCR was performed, and was negative. Hepatitis A serology showed evidence of immunity through previous infection or immunization. The patient was immune through vaccination for hepatitis B.

Despite her age, the history of a centripetal rash raised the possibility of measles, but both a nasopharyngeal swab (NPS) and a urine sample collected for measles PCR were negative. In addition, measles IgG showed evidence of prior infection/immunity. Dengue serology was ordered, and our patient was IgG positive and IgM negative, which is compatible with a history of previous flavivirus infection. PCR testing was then performed on the urine and NPS using a pan-flavivirus PCR targeting the NS5 gene (methodology previously described Footnote 17). Both the urine and NPS were positive, but the signal strength was 10 times stronger in the NPS sample. The 217 base pair amplicon was sequenced, with a 216/217 base pair (99%) match for Zika virus (GenBank accession no. KF993678.1).

This diagnosis of Zika virus infection was available one week after the initial infectious diseases consultation. Repeat dengue serology, two weeks after first presentation, was positive for both IgM and IgG.

Discussion

This is the first reported case of Zika virus in Canada related to the most recent outbreak in Central America, South America and the Caribbean.  Within a decade of the outbreak in Micronesia in 2007, Zika virus has been documented in several island nations in the South Pacific and, recently, in multiple countries in South and Central America. Zika virus is capable of transmission through numerous species of the Aedes genus, notably Aedes aegypti and Aedes albopictus Footnote 11. These species, which have adapted to urban and peri-urban environments, have been implicated in the rapid spread of chikungunya virus and dengue Footnote 18. Given the similarities in transmission vectors, it has been speculated that Zika virus has the potential to follow the epidemiological trends of these viruses and continue to gain footholds in Central America, the Caribbean and possibly more northern locales including parts of the southern United States Footnote 19. With ongoing transmission in Brazil and anticipated travel to the 2016 Rio de Janeiro Olympic Games, the potential for increasing incidence of imported cases in returning travellers is significant.

Clinical manifestations of Zika virus have been well characterized in previous outbreaks. The most common symptom described has been a macular or papular rash followed by subjective or measured fever Footnote 12. Of note, none of the temperatures of patients with confirmed Zika virus infection exceeded 37.9 °C in one prior outbreak Footnote 12. Other frequently described symptoms include arthralgias, conjunctivitis, myalgias, retro-orbital pain, and edema of the extremities Footnote 12Footnote 13. Symptoms typically last 3 to 12 days and overall disease course is thought to be milder than dengue or chikungunya Footnote 13; however, severe neurological complications including Guillain-Barre Syndrome have been described Footnote 12. In addition, the current epidemic in Brazil has now been linked to an increased incidence of congenital microcephaly Footnote 20 although further study is needed to confirm this association.

Given the non-specific clinical presentation of Zika virus infection, differentiating between Zika virus, dengue and chikungunya virus is difficult. Fever, rash, myalgias, arthralgias and retro-orbital pain are common symptoms of all three viruses. It has been suggested that extremity edema as well as conjunctivitis are more common in Zika virus Footnote 13 whereas severe arthralgias and persistent joint symptoms are more commonly associated with chikungunya Footnote 18. Cytopenias and lymphadenopathy are thought to be more common in dengue and chikungunya than in Zika virus infections Footnote 13. As well, the presence of a high fever may argue against Zika virus. Overt hemorrhagic fever has not been reported in association with Zika virus infection. Co-infection of Zika and dengue or other arboviruses is a concern given the common vector and geographic distribution. Differences in symptomatic presentation and disease severity due to co-infection are not known. In this case, the patient's primary symptoms of rash and fever abated one to two weeks after the initial onset of symptoms. The patient has noted ongoing mild generalized myalgias persisting past resolution of her other symptoms.

Supportive care with analgesics and antipyretics until symptom resolution is the mainstay of Zika virus infection management. Currently no directed treatment or vaccine is available. Zika virus infection is best prevented by avoiding mosquito vectors; travellers to endemic areas should wear long-sleeved clothing, use insect repellent and stay and sleep in screened-in or air-conditioned rooms.

Diagnosis of Zika virus is challenging as standard serologic testing cross-reacts significantly with other flaviviruses Footnote 12. In particular, dengue virus may present with a similar clinical syndrome and complicate serologic interpretation. A previous case in Canada described Zika virus in a traveller returning from Thailand, where a positive IgM for dengue initially led to a false diagnosis; this was corrected when the dengue IgG was persistently negative, leading the clinical team to investigate for other flaviviruses using molecular methods Footnote 21. In our patient, an initial negative IgM and a positive IgG for dengue likely reflects a history of dengue virus infection, with testing performed too early in the disease course to detect the cross-reacting IgM. Zika virus IgM typically develops within the first week of illness, and as our patient had only been ill for five days, the IgM response may not have developed at the time of testing Footnote 22. Repeat dengue IgM completed 19 days after illness onset was positive, showing the presence of acute cross-reacting Zika virus antibodies. A secondary flavivirus infection, as we were suspecting in our case, has been shown to induce a neutralizing antibody response with a greater degree of serologic cross‑reactivity against other flaviviruses, which could further complicate interpretation of serologic testing Footnote 22.

For travellers returning from areas endemic for both Zika and dengue virus, molecular methods are likely to be more helpful than serologic methods due to greater specificity and decreased turnaround time. The specimen recommended for Zika virus PCR is serum, during the first week after the onset of symptoms Footnote 23. Urine may be PCR positive for 10 days or longer after onset of symptoms Footnote 24. Testing from a NPS has been described, but it is unclear how long the virus will persist at this site Footnote 25. In our case, Zika virus was detected by the BCCDC Public Health Laboratory's PCR assay followed by amplicon sequencing. The sample was also sent to the National Microbiology Laboratory for confirmation. The NPS had a cycle threshold value of 27.46, a signal 10 times stronger than the urine, which had a cycle threshold value of 32.16. The results from molecular testing were also rapidly available, with the diagnosis of Zika virus made seven days after the initial assessment and specimen collection.

Conclusions

Zika virus is an emerging flavivirus that has become endemic in the Americas, having been recently documented in multiple countries across Central and South America. It should now be considered in all cases of returning travellers with fever and rash from these areas. Clinical presentation of Zika viral infection is similar to other medically important arboviruses including dengue and chikungunya virus. Measles can also have a similar presentation, posing additional challenges due to infection control implications. Serologic diagnosis is challenging given the cross-reaction with other flaviviruses, as well as the significant time delay in obtaining results. Prompt diagnosis is needed, as the differential diagnosis of fever and rash is broad in a returning traveller, and this would help to avoid unnecessary treatment or investigations. Molecular testing, with PCR and sequencing of the NS5 flavivirus gene, shows promise as a rapid and accurate diagnostic test for Zika virus, as well as for other flaviviruses. Given the possible association between Zika virus and microcephaly, pregnant women and women who could become pregnant should be counselled about this risk prior to travel to areas with documented Zika virus transmission. All travellers to these areas should be counselled on strategies to reduce exposure to mosquito vectors.

Acknowledgements

We gratefully acknowledge the assistance provided in this case by Stephanie Man, Dr. Patrick Doyle and the BC Centre for Disease Control as well as the National Microbiology Laboratory.

Conflict of interest

None.

Funding

None.

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: